AR089067A1 - Biomarcadores en el plasma sanguineo para terapias de combinacion de bevacizumab destinadas al tratamiento del cancer de mama - Google Patents
Biomarcadores en el plasma sanguineo para terapias de combinacion de bevacizumab destinadas al tratamiento del cancer de mamaInfo
- Publication number
- AR089067A1 AR089067A1 ARP120104537A ARP120104537A AR089067A1 AR 089067 A1 AR089067 A1 AR 089067A1 AR P120104537 A ARP120104537 A AR P120104537A AR P120104537 A ARP120104537 A AR P120104537A AR 089067 A1 AR089067 A1 AR 089067A1
- Authority
- AR
- Argentina
- Prior art keywords
- her2
- positive breast
- breast cancer
- cancer
- expression
- Prior art date
Links
Classifications
-
- G01N33/57515—
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Cell Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
Abstract
La presente proporciona métodos para mejorar el efecto del tratamiento de un régimen de quimioterapia de un paciente que sufre un cáncer de mama HER2-positivo, en particular cáncer de mama HER2-positivo localmente recurrente o metastásico, mediante la adición de bevacizumab (Avastin®) a un régimen de quimioterapia mediante la determinación del nivel de expresión, en particular el nivel de expresión en plasma sanguíneo, de VEGFA y/o de VEGFR2 respecto a los niveles de control de pacientes diagnosticados con cáncer de mama HER2-positivo, en particular cáncer de mama HER2-positivo localmente recurrente o metastásico. La presente proporciona además métodos para evaluar la sensibilidad o capacidad de respuesta de un paciente al bevacizumab (Avastin®) en combinación con un régimen de quimioterapia, mediante la determinación del nivel de expresión, en particular el nivel de expresión en plasma sanguíneo, de VEGFA y/o de VEGFR2 respecto a los niveles de control en pacientes diagnosticados con cáncer de mama HER2-positivo, en particular cáncer de mama HER2-positivo localmente recurrente o metastásico. Composición farmacéutica, kit.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11191922 | 2011-12-05 | ||
| EP12171293 | 2012-06-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR089067A1 true AR089067A1 (es) | 2014-07-30 |
Family
ID=47501094
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120104537A AR089067A1 (es) | 2011-12-05 | 2012-12-03 | Biomarcadores en el plasma sanguineo para terapias de combinacion de bevacizumab destinadas al tratamiento del cancer de mama |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20140341893A1 (es) |
| EP (1) | EP2788769A1 (es) |
| JP (1) | JP2015502543A (es) |
| KR (1) | KR20140094594A (es) |
| CN (1) | CN104067128A (es) |
| AR (1) | AR089067A1 (es) |
| AU (1) | AU2012348600A1 (es) |
| BR (1) | BR112014012623A2 (es) |
| CA (1) | CA2854598A1 (es) |
| IL (1) | IL232656A0 (es) |
| MX (1) | MX2014006500A (es) |
| RU (1) | RU2014125520A (es) |
| SG (1) | SG11201402737SA (es) |
| WO (1) | WO2013083499A1 (es) |
| ZA (1) | ZA201403602B (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015082880A1 (en) * | 2013-12-02 | 2015-06-11 | Astrazeneca Ab | Methods of selecting treatment regimens |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| AU2015328411C1 (en) | 2014-10-06 | 2022-03-03 | Dana-Farber Cancer Institute, Inc. | Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response |
| CA2966216A1 (en) * | 2014-11-14 | 2016-05-19 | Genentech, Inc. | Predicting response to a vegf antagonist |
| EP3229837B1 (en) | 2014-12-08 | 2025-02-05 | Dana-Farber Cancer Institute, Inc. | Methods for upregulating immune responses using combinations of anti-rgmb and anti-pd-1 agents |
| EP3362074B1 (en) | 2015-10-16 | 2023-08-09 | President and Fellows of Harvard College | Regulatory t cell pd-1 modulation for regulating t cell effector immune responses |
| CN108712911A (zh) | 2015-12-30 | 2018-10-26 | 科达制药股份有限公司 | 抗体及其缀合物 |
| CN110753755B (zh) | 2016-03-21 | 2023-12-29 | 丹娜法伯癌症研究院 | T细胞耗竭状态特异性基因表达调节子及其用途 |
| CN109477843A (zh) * | 2016-07-15 | 2019-03-15 | 豪夫迈·罗氏有限公司 | 用于检测总vegf-a的水平的方法和手段 |
| WO2019169341A1 (en) | 2018-03-02 | 2019-09-06 | Kodiak Sciences Inc. | Il-6 antibodies and fusion constructs and conjugates thereof |
| US11912784B2 (en) | 2019-10-10 | 2024-02-27 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| US20220390456A1 (en) * | 2019-10-17 | 2022-12-08 | Board Of Regents, The University Of Texas System | Small extracellular vesicle-associated vegf as a predictor for therapeutic responses |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE97498T1 (de) | 1984-01-30 | 1993-12-15 | Imp Cancer Res Tech | Verbesserungen an wachstumsfaktoren. |
| US5401638A (en) | 1986-06-04 | 1995-03-28 | Oncogene Science, Inc. | Detection and quantification of neu related proteins in the biological fluids of humans |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| JP3040121B2 (ja) | 1988-01-12 | 2000-05-08 | ジェネンテク，インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
| DE68926248T2 (de) | 1989-09-29 | 1996-12-19 | Oncogene Science Inc | p100 "neu" menschlisches Protein and Verwendung dieses Proteins zum Nachweis von preneoplasmatischen- oder neoplasmatischen beim Menschen |
| DE122004000008I1 (de) | 1991-06-14 | 2005-06-09 | Genentech Inc | Humanisierter Heregulin Antikörper. |
| US5635388A (en) | 1994-04-04 | 1997-06-03 | Genentech, Inc. | Agonist antibodies against the flk2/flt3 receptor and uses thereof |
| US5994071A (en) | 1997-04-04 | 1999-11-30 | Albany Medical College | Assessment of prostate cancer |
| DE19806989A1 (de) | 1998-02-19 | 1999-08-26 | Roche Diagnostics Gmbh | Erzeugung räumlich scharf begrenzter Festphasen für Bindungsassays |
| US20050106667A1 (en) | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
| DE102004029909A1 (de) | 2004-06-21 | 2006-01-19 | Roche Diagnostics Gmbh | Verfahren und Vorrichtung zur Herstellung von bindungsfähigen Reagenzträgern |
| ES2392630T3 (es) * | 2006-08-21 | 2012-12-12 | F. Hoffmann-La Roche Ag | Terapia antitumoral con anticuerpos anti-VEGF |
| BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
| EP2399129B1 (en) * | 2009-02-20 | 2015-11-25 | Michael P. Lisanti | A method of diagnosis or prognosis of a neoplasm comprising determining the level of expression of a protein in stromal cells adjacent to the neoplasm |
| US8427093B2 (en) * | 2010-07-02 | 2013-04-23 | Woodward Hrt, Inc. | Controller for actuation system employing Kalman estimator incorporating effect of system structural stiffness |
| WO2012010550A1 (en) * | 2010-07-19 | 2012-01-26 | F. Hoffmann-La Roche Ag | Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy |
| JP6055764B2 (ja) * | 2010-07-19 | 2016-12-27 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 乳癌の治療のためのベバシズマブ組合せ療法のための血漿バイオマーカー |
-
2012
- 2012-12-03 AU AU2012348600A patent/AU2012348600A1/en not_active Abandoned
- 2012-12-03 AR ARP120104537A patent/AR089067A1/es unknown
- 2012-12-03 WO PCT/EP2012/074184 patent/WO2013083499A1/en not_active Ceased
- 2012-12-03 CN CN201280067538.3A patent/CN104067128A/zh active Pending
- 2012-12-03 BR BR112014012623A patent/BR112014012623A2/pt unknown
- 2012-12-03 KR KR1020147015077A patent/KR20140094594A/ko not_active Withdrawn
- 2012-12-03 CA CA2854598A patent/CA2854598A1/en not_active Abandoned
- 2012-12-03 SG SG11201402737SA patent/SG11201402737SA/en unknown
- 2012-12-03 MX MX2014006500A patent/MX2014006500A/es unknown
- 2012-12-03 JP JP2014545192A patent/JP2015502543A/ja active Pending
- 2012-12-03 RU RU2014125520A patent/RU2014125520A/ru not_active Application Discontinuation
- 2012-12-03 EP EP12809640.1A patent/EP2788769A1/en not_active Withdrawn
-
2014
- 2014-05-15 IL IL232656A patent/IL232656A0/en unknown
- 2014-05-16 ZA ZA2014/03602A patent/ZA201403602B/en unknown
- 2014-05-28 US US14/289,524 patent/US20140341893A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2788769A1 (en) | 2014-10-15 |
| US20140341893A1 (en) | 2014-11-20 |
| CN104067128A (zh) | 2014-09-24 |
| NZ624444A (en) | 2016-07-29 |
| ZA201403602B (en) | 2015-04-29 |
| RU2014125520A (ru) | 2016-02-10 |
| SG11201402737SA (en) | 2014-06-27 |
| MX2014006500A (es) | 2014-08-21 |
| IL232656A0 (en) | 2014-06-30 |
| JP2015502543A (ja) | 2015-01-22 |
| WO2013083499A1 (en) | 2013-06-13 |
| AU2012348600A1 (en) | 2014-05-22 |
| CA2854598A1 (en) | 2013-06-13 |
| BR112014012623A2 (pt) | 2017-06-13 |
| KR20140094594A (ko) | 2014-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR089067A1 (es) | Biomarcadores en el plasma sanguineo para terapias de combinacion de bevacizumab destinadas al tratamiento del cancer de mama | |
| MX343801B (es) | Biomarcadores de plasma de sangre para terapias de combinacion con bevacizumab para tratamiento de cancer de mama. | |
| MX339427B (es) | Biomarcadores de plasma de sangre para terapias de combinacion con bevacizumab para tratamiento de cancer pancreatico. | |
| MX2012007940A (es) | Biomarcadores basados en tejido tumoral para terapias combinadas con bevacizumab. | |
| BR112016007864A2 (pt) | método para a prognose e tratamento de metástase de câncer | |
| BR112013004673A2 (pt) | biomarcadores e métodos de tratamento. | |
| MX2016002423A (es) | Composiciones y metodos de diagnostico para el tratamiento de glioblastoma. | |
| MX358541B (es) | Metodos para predecir el riesgo de desarrollar hipertension. | |
| MX383886B (es) | Anticuerpo anti-trop-2 humano que tiene una actividad antitumoral in vivo. | |
| TN2013000464A1 (en) | Biomarkers for hedgehog inhibitor therapy | |
| BR112016002000A2 (pt) | Diagnóstico e terapia de câncer envolvendo células-tronco tumorais | |
| MX2016012285A (es) | Tratamiento de cáncer con antagonista de c-met y correlación de estos con la expresión de hgf. | |
| MX362514B (es) | Kits y ensayos de diagnostico para la deteccion del receptor 1 de folato. | |
| BR112014024219A8 (pt) | Métodos de determinação, de otimização da eficácia terapêutica, de monitoramento, de seleção de terapia e de diagnóstico de distúrbio e kit | |
| MX360236B (es) | Uso de marcadores en el diagnostico y tratamiento de cancer de prostata. | |
| WO2011094759A3 (en) | Novel diagnostic and therapeutic targets associated with or regulated by n-cadherin expression and/or epithelial to mesenchymal transition (emt) in prostate cancer and other malignancies | |
| BR112014025189A2 (pt) | prognóstico de eventos adversos em pacientes com suspeita de insuficiência cardíaca crônica | |
| WO2012109632A3 (en) | Crown-like structures as a biomarker for cancer risk and cancer prognosis | |
| ES2570631T3 (es) | Procedimiento de determinación de la apolipoproteína AII para el diagnóstico in vitro del cáncer colorrectal | |
| PH12015500388A1 (en) | Cancer diagnostic and therapeutic method targeting molecules expressed in cancer stem cells | |
| BR112014018374A8 (pt) | Método para predizer a resposta d eum paciente com câncer, kit, anticorpo, método para o tratamento do câncer e composição farmacêutica | |
| MX2016002529A (es) | Marcadores de riesgo para cardiovasculopatias en pacientes con nefropatia cronica. | |
| BR112015031950A2 (pt) | métodos para tratamento de câncer de ovário | |
| BR112015027249A2 (pt) | método de diagnóstico de câncer | |
| WO2012138691A3 (en) | Diagnosis and treatment of taxane-resistant cancers |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |